{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:43:24Z","timestamp":1794973404279,"version":"4.9.1"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and\/or switching between these therapies are addressed.<\/jats:p>","DOI":"10.1186\/s10194-023-01644-8","type":"journal-article","created":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T19:02:17Z","timestamp":1694372537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Mode and site of action of therapies targeting CGRP signaling"],"prefix":"10.1186","volume":"24","author":[{"given":"Alejandro","family":"Labastida-Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Gollion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Stanyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austeja","family":"Dapkute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Braniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Naghshineh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liga","family":"Meksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Chkhitunidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamari","family":"Gudadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","volume":"298","author":"SG Amara","year":"1982","unstructured":"Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240\u2013244","journal-title":"Nature"},{"key":"1644_CR2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/sj.bjp.0705040","volume":"138","author":"SG Howitt","year":"2003","unstructured":"Howitt SG, Kilk K, Wang Y, Smith DM, Langel U, Poyner DR (2003) The role of the 8\u201318 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. Br J Pharmacol 138:325\u2013332","journal-title":"Br J Pharmacol"},{"key":"1644_CR3","first-page":"718","volume":"251","author":"T Dennis","year":"1989","unstructured":"Dennis T, Fournier A, St Pierre S, Quirion R (1989) Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity. J Pharmacol Exp Ther 251:718\u2013725","journal-title":"J Pharmacol Exp Ther"},{"key":"1644_CR4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-7634(96)00023-1","volume":"21","author":"D Van Rossum","year":"1997","unstructured":"Van Rossum D, Hanisch UK, Quirion R (1997) Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21:649\u2013678","journal-title":"Neurosci Biobehav Rev"},{"key":"1644_CR5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0014-5793(85)80820-6","volume":"183","author":"P Steenbergh","year":"1985","unstructured":"Steenbergh P, H\u00f6ppener J, Zandberg J, Lips C, Jansz H (1985) A second human calcitonin\/CGRP gene. FEBS Lett 183:408\u2013412","journal-title":"FEBS Lett"},{"key":"1644_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-5793(86)81338-2","volume":"206","author":"M Alevizaki","year":"1986","unstructured":"Alevizaki M, Shiraishi A, Rassool FV, Ferner GJ, Maclntyre I, Legon S (1986) The calcitonin-like sequence of the \u03b2 CGRP gene. FEBS Lett 206:47\u201352","journal-title":"FEBS Lett"},{"key":"1644_CR7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103:1565\u20131644","journal-title":"Physiol Rev"},{"key":"1644_CR8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1152\/jn.1998.79.2.964","volume":"79","author":"R Burstein","year":"1998","unstructured":"Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79:964\u2013982","journal-title":"J Neurophysiol"},{"key":"1644_CR9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1152\/jn.01293.2005","volume":"95","author":"AM Strassman","year":"2006","unstructured":"Strassman AM, Levy D (2006) Response properties of dural nociceptors in relation to headache. J Neurophysiol 95:1298\u20131306","journal-title":"J Neurophysiol"},{"key":"1644_CR10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-8993(83)90402-X","volume":"268","author":"L-Y Liu-Chen","year":"1983","unstructured":"Liu-Chen L-Y, Mayberg MR, Moskowitz MA (1983) Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats. Brain Res 268:162\u2013166","journal-title":"Brain Res"},{"key":"1644_CR11","doi-asserted-by":"crossref","first-page":"R270","DOI":"10.1152\/ajpregu.1987.253.2.R270","volume":"253","author":"P Goadsby","year":"1987","unstructured":"Goadsby P, Duckworth J (1987) Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol Regul Integr Comp Physiol 253:R270\u2013R274","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1644_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-neuro-080422-105509","volume":"46","author":"D Levy","year":"2023","unstructured":"Levy D, Moskowitz MA (2023) Meningeal mechanisms and the migraine connection. Annu Rev Neurosci 46:39\u201358","journal-title":"Annu Rev Neurosci"},{"key":"1644_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"MG Rosenfeld","year":"1983","unstructured":"Rosenfeld MG, Mermod J-J, Amara SG, Swanson LW, Sawchenko PE, Rivier J et al (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129\u2013135","journal-title":"Nature"},{"key":"1644_CR14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene\u2013related peptide in peripheral and central pain mechanisms including migraine. Pain 158:543\u2013559","journal-title":"Pain"},{"key":"1644_CR15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0006-8993(86)90423-3","volume":"374","author":"S Inagaki","year":"1986","unstructured":"Inagaki S, Kito S, Kubota Y, Girgis S, Hillyard CJ, Macintyre I (1986) Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res 374:287\u2013298","journal-title":"Brain Res"},{"key":"1644_CR16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.neuroscience.2010.05.016","volume":"169","author":"S Eftekhari","year":"2010","unstructured":"Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L (2010) Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169:683\u2013696","journal-title":"Neuroscience"},{"key":"1644_CR17","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/j.pain.0000000000001973","volume":"161","author":"S Shiers","year":"2020","unstructured":"Shiers S, Klein RM, Price TJ (2020) Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated with RNAscope in situ hybridization. Pain 161:2410\u20132424","journal-title":"Pain"},{"key":"1644_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-021-01365-w","volume":"23","author":"A Wiggers","year":"2022","unstructured":"Wiggers A, Ashina H, Hadjikhani N, Sagare A, Zlokovic BV, Lauritzen M et al (2022) Brain barriers and their potential role in migraine pathophysiology. J Headache Pain 23:1\u201310","journal-title":"J Headache Pain"},{"key":"1644_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s10194-021-01320-9","volume":"22","author":"M Risch","year":"2021","unstructured":"Risch M, Vogler B, Dux M, Messlinger K (2021) CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater. J Headache Pain 22:105","journal-title":"J Headache Pain"},{"key":"1644_CR20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0333102419896760","volume":"40","author":"R Noseda","year":"2020","unstructured":"Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F et al (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40:229\u2013240","journal-title":"Cephalalgia"},{"key":"1644_CR21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41467-022-28204-z","volume":"13","author":"F De Logu","year":"2022","unstructured":"De Logu F, Nassini R, Hegron A, Landini L, Jensen DD, Latorre R et al (2022) Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice. Nat Commun 13:646","journal-title":"Nat Commun"},{"key":"1644_CR22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0304-3940(85)90166-1","volume":"58","author":"L Edvinsson","year":"1985","unstructured":"Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C (1985) Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 58:213\u2013217","journal-title":"Neurosci Lett"},{"key":"1644_CR23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0304-3940(85)90045-X","volume":"57","author":"J Hanko","year":"1985","unstructured":"Hanko J, Hardebo JE, K\u00e5hrstr\u00f6m J, Owman C, Sundler F (1985) Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibres and dilates pial and peripheral arteries. Neurosci Lett 57:91\u201395","journal-title":"Neurosci Lett"},{"key":"1644_CR24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/313054a0","volume":"313","author":"S Brain","year":"1985","unstructured":"Brain S, Williams T, Tippins J, Morris H, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54\u201356","journal-title":"Nature"},{"key":"1644_CR25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1526-4610.1987.hed2704180.x","volume":"27","author":"F Sicuteri","year":"1987","unstructured":"Sicuteri F, Del Bene E, Poggioni M, Bonazzi A (1987) Unmasking latent dysnociception in healthy subjects. Headache 27:180\u2013185","journal-title":"Headache"},{"key":"1644_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pain.2003.09.008","volume":"106","author":"G Juhasz","year":"2003","unstructured":"Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J et al (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106:461\u2013470","journal-title":"Pain"},{"key":"1644_CR27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"P Goadsby","year":"1990","unstructured":"Goadsby P, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183\u2013187","journal-title":"Ann Neurol"},{"key":"1644_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48\u201356","journal-title":"Ann Neurol"},{"key":"1644_CR29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0333102413520084","volume":"34","author":"JM Hansen","year":"2014","unstructured":"Hansen JM, Ashina M (2014) Calcitonin gene-related peptide and migraine with aura: a systematic review. Cephalalgia 34:695\u2013707","journal-title":"Cephalalgia"},{"key":"1644_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/head.13077","volume":"57","author":"DL Hay","year":"2017","unstructured":"Hay DL (2017) Amylin. Headache 57:89\u201396","journal-title":"Headache"},{"key":"1644_CR31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acsptsci.9b00089","volume":"3","author":"JJ Gingell","year":"2020","unstructured":"Gingell JJ, Rees TA, Hendrikse ER, Siow A, Rennison D, Scotter J et al (2020) Distinct patterns of internalization of different calcitonin gene-related peptide receptors. ACS Pharmacol Transl Sci 3:296\u2013304","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1644_CR32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-030-69032-8_2","volume-title":"Monoclonal antibodies in headache: from bench to patient","author":"A Labastida-Ram\u00edrez","year":"2021","unstructured":"Labastida-Ram\u00edrez A (2021) Pharmacology; where do the mAbs Act, Gepants Versus mAbs. In: Maassen van den Brink A, Martelletti P (eds) Monoclonal antibodies in headache: from bench to patient. Springer International Publishing, Cham, pp 13\u201323"},{"key":"1644_CR33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-018-0535-y","volume":"561","author":"Y-L Liang","year":"2018","unstructured":"Liang Y-L, Khoshouei M, Deganutti G, Glukhova A, Koole C, Peat TS et al (2018) Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature 561:492\u2013497","journal-title":"Nature"},{"key":"1644_CR34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","volume":"393","author":"LM McLatchie","year":"1998","unstructured":"McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N et al (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333\u2013339","journal-title":"Nature"},{"key":"1644_CR35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/0333102417728873","volume":"39","author":"K Warfvinge","year":"2019","unstructured":"Warfvinge K, Edvinsson L (2019) Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia 39:342\u2013353","journal-title":"Cephalalgia"},{"key":"1644_CR36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bph.15585","volume":"179","author":"ML Garelja","year":"2022","unstructured":"Garelja ML, Walker CS, Hay DL (2022) CGRP receptor antagonists for migraine. Are they also AMY(1) receptor antagonists? Br J Pharmacol 179:454\u2013459","journal-title":"Br J Pharmacol"},{"key":"1644_CR37","doi-asserted-by":"crossref","first-page":"860037","DOI":"10.3389\/fphys.2022.860037","volume":"13","author":"TA Rees","year":"2022","unstructured":"Rees TA, Russo AF, O\u2019Carroll SJ, Hay DL, Walker CS (2022) CGRP and the calcitonin receptor are co-expressed in mouse, rat and human trigeminal ganglia neurons. Front Physiol 13:860037","journal-title":"Front Physiol"},{"key":"1644_CR38","doi-asserted-by":"crossref","first-page":"R697","DOI":"10.1152\/ajpregu.00338.2020","volume":"320","author":"TA Rees","year":"2021","unstructured":"Rees TA, Hay DL, Walker CS (2021) Amylin antibodies frequently display cross-reactivity with CGRP: characterization of eight amylin antibodies. Am J Physiol Regul Integr Comp Physiol 320:R697-r703","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1644_CR39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","volume":"1600","author":"S Eftekhari","year":"2015","unstructured":"Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L (2015) Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 1600:93\u2013109","journal-title":"Brain Res"},{"key":"1644_CR40","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1177\/0333102418771350","volume":"39","author":"D Levy","year":"2019","unstructured":"Levy D, Labastida-Ramirez A, MaassenVanDenBrink A (2019) Current understanding of meningeal and cerebral vascular function underlying migraine headache. Cephalalgia 39:1606\u20131622","journal-title":"Cephalalgia"},{"key":"1644_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-018-0848-0","volume":"19","author":"K Messlinger","year":"2018","unstructured":"Messlinger K (2018) The big CGRP flood-sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain 19:1\u20137","journal-title":"J Headache Pain"},{"key":"1644_CR42","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12031-020-01493-z","volume":"70","author":"L Edvinsson","year":"2020","unstructured":"Edvinsson L, Grell A-S, Warfvinge K (2020) Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci 70:930\u2013944","journal-title":"J Mol Neurosci"},{"key":"1644_CR43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jpain.2013.03.010","volume":"14","author":"S Eftekhari","year":"2013","unstructured":"Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289\u20131303","journal-title":"J Pain"},{"key":"1644_CR44","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, Strassman AM, Nir R-R, Schain AJ, Noseda R, Stratton J et al (2017) Fremanezumab\u2014a humanized monoclonal anti-CGRP antibody\u2014inhibits thinly myelinated (A\u03b4) but not unmyelinated (C) meningeal nociceptors. J Neurosci 37:10587\u201310596","journal-title":"J Neurosci"},{"key":"1644_CR45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1507\/endocrj1954.36.409","volume":"36","author":"K Takahashi","year":"1989","unstructured":"Takahashi K, Mouri T, Sone M, Murakami O, Itoi K, Imai Y et al (1989) Calcitonin gene-related peptide in the human hypothalamus. Endocrinol Jpn 36:409\u2013415","journal-title":"Endocrinol Jpn"},{"key":"1644_CR46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mcn.2010.10.005","volume":"46","author":"L Edvinsson","year":"2011","unstructured":"Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K (2011) Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci 46:333\u2013339","journal-title":"Mol Cell Neurosci"},{"key":"1644_CR47","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104\u20131110","journal-title":"N Engl J Med"},{"key":"1644_CR48","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","volume":"70","author":"TW Ho","year":"2008","unstructured":"Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304\u20131312","journal-title":"Neurology"},{"key":"1644_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H et al (2022) Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia 42:3\u201311","journal-title":"Cephalalgia"},{"key":"1644_CR50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51\u201360","journal-title":"Lancet"},{"key":"1644_CR51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/1871527319666200618144637","volume":"19","author":"A Gonz\u00e1lez-Hern\u00e1ndez","year":"2020","unstructured":"Gonz\u00e1lez-Hern\u00e1ndez A, Marichal-Cancino BA, Garc\u00eda-Boll E, Villal\u00f3n CM (2020) The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms. CNS Neurol Disord Drug Targets 19:344\u2013359","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1644_CR52","doi-asserted-by":"crossref","first-page":"333102423115216","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43:3331024231152169","journal-title":"Cephalalgia"},{"key":"1644_CR53","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.medidd.2020.100053","volume":"7","author":"D Moreno-Ajona","year":"2020","unstructured":"Moreno-Ajona D, P\u00e9rez-Rodr\u00edguez A, Goadsby PJ (2020) Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine. Med Drug Discov 7:100053","journal-title":"Med Drug Discov"},{"key":"1644_CR54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22:209\u2013217","journal-title":"Lancet Neurol"},{"key":"1644_CR55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/0333102420983282","volume":"41","author":"M Bhakta","year":"2021","unstructured":"Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD (2021) Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia 41:499\u2013514","journal-title":"Cephalalgia"},{"key":"1644_CR56","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","volume":"11","author":"KS Pan","year":"2020","unstructured":"Pan KS, Siow A, Hay DL, Walker CS (2020) Antagonism of CGRP signaling by rimegepant at two receptors. Front Pharmacol 11:1240","journal-title":"Front Pharmacol"},{"key":"1644_CR57","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/03331024221083544","volume":"42","author":"AM Strassman","year":"2022","unstructured":"Strassman AM, Melo-Carrillo A, Houle TT, Adams A, Brin MF, Burstein R (2022) Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD. Cephalalgia 42:933\u2013943","journal-title":"Cephalalgia"},{"key":"1644_CR58","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/awq224","volume":"133","author":"O Summ","year":"2010","unstructured":"Summ O, Charbit AR, Andreou AP, Goadsby PJ (2010) Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133:2540\u20132548","journal-title":"Brain"},{"key":"1644_CR59","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1523\/JNEUROSCI.0869-05.2005","volume":"25","author":"MJ Fischer","year":"2005","unstructured":"Fischer MJ, Koulchitsky S, Messlinger K (2005) The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 25:5877\u20135883","journal-title":"J Neurosci"},{"key":"1644_CR60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0006-8993(00)02473-2","volume":"873","author":"Y Huang","year":"2000","unstructured":"Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC (2000) Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res 873:54\u201359","journal-title":"Brain Res"},{"key":"1644_CR61","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1177\/0333102415576723","volume":"35","author":"P Pozo-Rosich","year":"2015","unstructured":"Pozo-Rosich P, Storer RJ, Charbit AR, Goadsby PJ (2015) Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia 35:1298\u20131307","journal-title":"Cephalalgia"},{"key":"1644_CR62","doi-asserted-by":"crossref","first-page":"11408","DOI":"10.1038\/s41598-020-67948-w","volume":"10","author":"C Tang","year":"2020","unstructured":"Tang C, Unekawa M, Kitagawa S, Takizawa T, Kayama Y, Nakahara J et al (2020) Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant. Sci Rep 10:11408","journal-title":"Sci Rep"},{"key":"1644_CR63","first-page":"136","volume":"29","author":"C Sur","year":"2009","unstructured":"Sur C, Hargreaves R, Bell I, Dancho M, Graham S, Hostetler E et al (2009) CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer: PO326. Cephalalgia 29:136\u2013137","journal-title":"Cephalalgia"},{"key":"1644_CR64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1124\/jpet.113.206458","volume":"347","author":"ED Hostetler","year":"2013","unstructured":"Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M et al (2013) In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C] MK-4232. J Pharmacol Exp Ther 347:478\u2013486","journal-title":"J Pharmacol Exp Ther"},{"key":"1644_CR65","doi-asserted-by":"crossref","first-page":"P224","DOI":"10.1186\/1129-2377-14-S1-P224","volume":"14","author":"SGG Vermeersch","year":"2013","unstructured":"Vermeersch SGG, de Hoon J, De Saint-Hubert B, Derdelinckx I, Serdons K, Bormans G et al (2013) PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 14:P224\u2013P224","journal-title":"J Headache Pain"},{"key":"1644_CR66","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/head.13510","volume":"59","author":"R Hargreaves","year":"2019","unstructured":"Hargreaves R, Olesen J (2019) Calcitonin gene-related peptide modulators\u2013the history and renaissance of a new migraine drug class. Headache 59:951\u2013970","journal-title":"Headache"},{"key":"1644_CR67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0169-328X(01)00179-6","volume":"93","author":"T Ueda","year":"2001","unstructured":"Ueda T, Ugawa S, Saishin Y, Shimada S (2001) Expression of receptor-activity modifying protein (RAMP) mRNAs in the mouse brain. Brain Res Mol Brain Res 93:36\u201345","journal-title":"Brain Res Mol Brain Res"},{"key":"1644_CR68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1054-3589(05)52003-9","volume":"52","author":"A Young","year":"2005","unstructured":"Young A (2005) Receptor pharmacology. Adv Pharmacol 52:47\u201365","journal-title":"Adv Pharmacol"},{"key":"1644_CR69","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125)I] galcanezumab in male rats. Cephalalgia 39:1241\u20131248","journal-title":"Cephalalgia"},{"key":"1644_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ncl.2020.09.001","volume":"39","author":"E Caronna","year":"2021","unstructured":"Caronna E, Starling AJ (2021) Update on calcitonin gene-related peptide antagonism in the treatment of migraine. Neurol Clin 39:1\u201319","journal-title":"Neurol Clin"},{"key":"1644_CR71","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ (2022) New generation gepants: migraine acute and preventive medications. J Clin Med 11:1656","journal-title":"J Clin Med"},{"key":"1644_CR72","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.celrep.2020.01.029","volume":"30","author":"F Garces","year":"2020","unstructured":"Garces F, Mohr C, Zhang L, Huang C-S, Chen Q, King C et al (2020) Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (Erenumab). Cell Rep 30:1714\u20131723 e1716","journal-title":"Cell Rep"},{"key":"1644_CR73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP et al (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356:223\u2013231","journal-title":"J Pharmacol Exp Ther"},{"key":"1644_CR74","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/acn3.197","volume":"2","author":"CS Walker","year":"2015","unstructured":"Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L et al (2015) A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2:595\u2013608","journal-title":"Ann Clin Transl Neurol"},{"key":"1644_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-021-01295-7","volume":"22","author":"D Scuteri","year":"2021","unstructured":"Scuteri D, Corasaniti MT, Tonin P, Nicotera P, Bagetta G (2021) Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy. J Headache Pain 22:1\u201314","journal-title":"J Headache Pain"},{"key":"1644_CR76","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1080\/21655979.2021.2006977","volume":"12","author":"L David","year":"2021","unstructured":"David L, Scalley-Kim M, Olland A, White A, Misura K (2021) The eptinezumab: CGRP complex structure\u2013the role of conformational changes in binding stabilization. Bioengineered 12:11076\u201311086","journal-title":"Bioengineered"},{"key":"1644_CR77","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/head.14388","volume":"62","author":"ML Garelja","year":"2022","unstructured":"Garelja ML, Hay DL (2022) A narrative review of the calcitonin peptide family and associated receptors as migraine targets: calcitonin gene-related peptide and beyond. Headache 62:1093\u20131104","journal-title":"Headache"},{"key":"1644_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-019-0992-1","volume":"20","author":"R Manoukian","year":"2019","unstructured":"Manoukian R, Sun H, Miller S, Shi D, Chan B, Xu C (2019) Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking. J Headache Pain 20:1\u201312","journal-title":"J Headache Pain"},{"key":"1644_CR79","doi-asserted-by":"crossref","first-page":"12309","DOI":"10.1073\/pnas.1706656114","volume":"114","author":"RE Yarwood","year":"2017","unstructured":"Yarwood RE, Imlach WL, Lieu T, Veldhuis NA, Jensen DD, Klein Herenbrink C et al (2017) Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. Proc Natl Acad Sci U S A 114:12309\u201312314","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1644_CR80","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","volume":"94","author":"K Mullin","year":"2020","unstructured":"Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V et al (2020) Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 94:e2121\u2013e2125","journal-title":"Neurology"},{"key":"1644_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01193-4","volume":"21","author":"G Tringali","year":"2020","unstructured":"Tringali G, Vollono C, Calabresi P, Navarra P (2020) A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. J Headache Pain 21:1\u20132","journal-title":"J Headache Pain"},{"key":"1644_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-021-01374-9","volume":"23","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, Garrelds IM, Danser A, Terwindt GM, MaassenVanDenBrink A (2022) Serum CGRP in migraine patients using erenumab as preventive treatment. J Headache Pain 23:1\u20137","journal-title":"J Headache Pain"},{"key":"1644_CR83","doi-asserted-by":"crossref","unstructured":"G\u00e1rate G, Gonz\u00e1lez-Quintanilla V, Gonz\u00e1lez A, Pascual M, P\u00e9rez-Pereda S, Madera J et al (2023) Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol 94:285\u2013294","DOI":"10.1002\/ana.26658"},{"key":"1644_CR84","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1476-5381.2010.01012.x","volume":"161","author":"S Gupta","year":"2010","unstructured":"Gupta S, Amrutkar DV, Mataji A, Salmasi H, Hay-Schmidt A, Sheykhzade M et al (2010) Evidence for CGRP re-uptake in rat dura mater encephali. Br J Pharmacol 161:1885\u20131898","journal-title":"Br J Pharmacol"},{"key":"1644_CR85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system\u201440 years and counting. Lancet Neurol 18:795\u2013804","journal-title":"Lancet Neurol"},{"key":"1644_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-018-0905-8","volume":"19","author":"L Ohlsson","year":"2018","unstructured":"Ohlsson L, Kronvall E, Stratton J, Edvinsson L (2018) Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain 19:1\u20136","journal-title":"J Headache Pain"},{"key":"1644_CR87","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1523\/JNEUROSCI.0576-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, Noseda R, Nir R-R, Schain AJ, Stratton J, Strassman AM et al (2017) Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci 37:7149\u20137163","journal-title":"J Neurosci"},{"key":"1644_CR88","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/03331024221111526","volume":"42","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, De Cesaris F, Ferrari A, Benemei S, Fattori D, Chiarugi A (2022) Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia 42:1323\u20131330","journal-title":"Cephalalgia"},{"key":"1644_CR89","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s10194-022-01421-z","volume":"23","author":"M de Tommaso","year":"2022","unstructured":"de Tommaso M, La Rocca M, Quitadamo SG, Ricci K, Tancredi G, Clemente L et al (2022) Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients. J Headache Pain 23:52","journal-title":"J Headache Pain"},{"key":"1644_CR90","doi-asserted-by":"crossref","first-page":"e77146","DOI":"10.7554\/eLife.77146","volume":"11","author":"H Basedau","year":"2022","unstructured":"Basedau H, Sturm L-M, Mehnert J, Peng K-P, Schellong M, May A (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target\u2013an fMRI study. Elife 11:e77146","journal-title":"Elife"},{"key":"1644_CR91","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1474-4422(22)00294-0","volume":"21","author":"ASS Andersen","year":"2022","unstructured":"Andersen ASS, Maarbjerg S, Noory N, Heinskou TB, Forman JL, Cruccu G et al (2022) Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lancet Neurol 21:994\u20131003","journal-title":"Lancet Neurol"},{"key":"1644_CR92","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA et al (2019) Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 381:132\u2013141","journal-title":"N Engl J Med"},{"key":"1644_CR93","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM et al (2020) Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia 40:935\u2013948","journal-title":"Cephalalgia"},{"key":"1644_CR94","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/head.14404","volume":"62","author":"JA Membrilla","year":"2022","unstructured":"Membrilla JA, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (2022) Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: case series and narrative review. Headache 62:1395\u2013405","journal-title":"Headache"},{"key":"1644_CR95","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2021) Efficacy of Erenumab in Chronic Cluster Headache (CHERUB01). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04970355"},{"key":"1644_CR96","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2021) A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) (CHRONICLE). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05064397"},{"key":"1644_CR97","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2020) Eptinezumab in Participants With Episodic Cluster Headache (ALLEVIATE). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04688775"},{"key":"1644_CR98","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2016) A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02945046"},{"key":"1644_CR99","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2016) A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02964338"},{"key":"1644_CR100","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/0333102420981688","volume":"41","author":"CM Kopruszinski","year":"2021","unstructured":"Kopruszinski CM, Turnes JM, Swiokla J, Weinstein TJ, Schwedt TJ, Dodick DW et al (2021) CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. Cephalalgia 41:749\u2013759","journal-title":"Cephalalgia"},{"key":"1644_CR101","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1177\/0333102419877662","volume":"39","author":"E Navratilova","year":"2019","unstructured":"Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J et al (2019) CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia 39:1762\u20131775","journal-title":"Cephalalgia"},{"key":"1644_CR102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s10194-020-01136-z","volume":"21","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Al-Khazali HM, Eigenbrodt AK, Larsen EL, Andersen AM et al (2020) Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain 21:62","journal-title":"J Headache Pain"},{"key":"1644_CR103","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2021) Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05049057"},{"key":"1644_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov (2017) A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03347188"},{"key":"1644_CR105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01182-7","volume":"21","author":"A Yiangou","year":"2020","unstructured":"Yiangou A, Mitchell JL, Vijay V, Grech O, Bilton E, Lavery GG et al (2020) Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain 21:1\u20138","journal-title":"J Headache Pain"},{"key":"1644_CR106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/head.14026","volume":"61","author":"A Yiangou","year":"2021","unstructured":"Yiangou A, Mitchell JL, Fisher C, Edwards J, Vijay V, Alimajstorovic Z et al (2021) Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache 61:157\u2013169","journal-title":"Headache"},{"key":"1644_CR107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltr\u00e1n","year":"2018","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Villal\u00f3n CM, MaassenVanDenBrink A (2018) Is selective 5-HT(1F) receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88\u201397","journal-title":"Pharmacol Ther"},{"key":"1644_CR108","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"SJ Tepper","year":"2002","unstructured":"Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B\/1D receptor agonists. Arch Neurol 59:1084\u20131088","journal-title":"Arch Neurol"},{"key":"1644_CR109","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.neuroscience.2009.03.019","volume":"161","author":"P Goadsby","year":"2009","unstructured":"Goadsby P, Charbit A, Andreou A, Akerman S, Holland P (2009) Neurobiology of migraine. Neuroscience 161:327\u2013341","journal-title":"Neuroscience"},{"key":"1644_CR110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM (2020) Lasmiditan mechanism of action - review of a selective 5-HT(1F) agonist. J Headache Pain 21:71","journal-title":"J Headache Pain"},{"key":"1644_CR111","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","volume":"161","author":"A Labastida-Ram\u00edrez","year":"2020","unstructured":"Labastida-Ram\u00edrez A, Rubio-Beltr\u00e1n E, Haanes KA, Chan KY, Garrelds IM, Johnson KW et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 161:1092\u20131099","journal-title":"Pain"},{"key":"1644_CR112","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fneur.2016.00173","volume":"7","author":"HO Usman","year":"2016","unstructured":"Usman HO, Balaban CD (2016) Distribution of 5-HT1F receptors in monkey vestibular and trigeminal ganglion cells. Front Neurol 7:173","journal-title":"Front Neurol"},{"key":"1644_CR113","first-page":"333102423116174","volume":"43","author":"M Ashina","year":"2023","unstructured":"Ashina M, Roos C, Li LQ, Komori M, Ayer D, Ruff D et al (2023) Long-term treatment with lasmiditan in patients with migraine: results from the open-label extension of the CENTURION randomized trial. Cephalalgia 43:3331024231161745","journal-title":"Cephalalgia"},{"key":"1644_CR114","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bph.14832","volume":"176","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Haanes KA, van den Bogaerdt A, Bogers A, Zanelli E et al (2019) Characterization of binding, functional activity, and contractile responses of the selective 5-HT(1F) receptor agonist lasmiditan. Br J Pharmacol 176:4681\u20134695","journal-title":"Br J Pharmacol"},{"key":"1644_CR115","doi-asserted-by":"crossref","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Liang C-S, Chang C-M, Yang C-C, Shih P-H, Yau Y-C et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4:e2128544\u2013e2128544","journal-title":"JAMA Netw Open"},{"key":"1644_CR116","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","volume":"15","author":"T Sprenger","year":"2018","unstructured":"Sprenger T, Viana M, Tassorelli C (2018) Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 15:313\u2013323","journal-title":"Neurotherapeutics"},{"key":"1644_CR117","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acn3.51640","volume":"9","author":"E Rubio-Beltr\u00e1n","year":"2022","unstructured":"Rubio-Beltr\u00e1n E, Schoon RM, van den Berg J, Schuiling-Veninga CC, Koch BC, Villal\u00f3n CM et al (2022) Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol 9:1405\u20131416","journal-title":"Ann Clin Transl Neurol"},{"key":"1644_CR118","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","volume":"156","author":"E Cernuda-Moroll\u00f3n","year":"2015","unstructured":"Cernuda-Moroll\u00f3n E, Ram\u00f3n C, Mart\u00ednez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J (2015) OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156:820\u2013824","journal-title":"Pain"},{"key":"1644_CR119","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Moroll\u00f3n","year":"2013","unstructured":"Cernuda-Moroll\u00f3n E, Larrosa D, Ram\u00f3n C, Vega J, Mart\u00ednez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81:1191\u20131196","journal-title":"Neurology"},{"key":"1644_CR120","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1526-4610.2006.00538.x","volume":"46","author":"PL Durham","year":"2006","unstructured":"Durham PL, Niemann C, Cady R (2006) Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache 46:1291\u20131295","journal-title":"Headache"},{"key":"1644_CR121","first-page":"153","volume":"65","author":"DA Garcia-Estevez","year":"2017","unstructured":"Garcia-Estevez DA, Pardo-Parrado M, Silvarrey-Rodriguez S (2017) Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide. Rev Neurol 65:153\u2013156","journal-title":"Rev Neurol"},{"key":"1644_CR122","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0333102419873675","volume":"39","author":"A Melo-Carrillo","year":"2019","unstructured":"Melo-Carrillo A, Strassman AM, Schain AJ, Noseda R, Ashina S, Adams A et al (2019) Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia 39:1358\u20131365","journal-title":"Cephalalgia"},{"key":"1644_CR123","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","volume":"44","author":"PL Durham","year":"2004","unstructured":"Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 44:35\u201343","journal-title":"Headache"},{"key":"1644_CR124","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Do TP, Ashina H, Ashina M, Burstein R (2020) Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache 60:1056\u20131065","journal-title":"Headache"},{"key":"1644_CR125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/toxins14120847","volume":"14","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M (2022) OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins 14:847","journal-title":"Toxins"},{"key":"1644_CR126","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/brain\/awab461","volume":"145","author":"L Gfrerer","year":"2021","unstructured":"Gfrerer L, Xu W, Austen W Jr, Ashina S, Melo-Carrillo A, Longhi MS et al (2021) OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients. Brain 145:2436\u20132449","journal-title":"Brain"},{"key":"1644_CR127","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0028-3908(94)90068-X","volume":"33","author":"N Adham","year":"1994","unstructured":"Adham N, Tamm JA, Salon JA, Vaysse PJ, Weinshank RL, Branchek TA (1994) A single point mutation increases the affinity of serotonin 5-HT1D alpha, 5-HT1D beta, 5-HT1E and 5-HT1F receptors for beta-adrenergic antagonists. Neuropharmacology 33:387\u2013391","journal-title":"Neuropharmacology"},{"key":"1644_CR128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1468-2982.1997.1702093.x","volume":"17","author":"FM Cutrer","year":"1997","unstructured":"Cutrer FM, Limmroth V, Moskowitz MA (1997) Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 17:93\u2013100","journal-title":"Cephalalgia"},{"key":"1644_CR129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jnr.490240111","volume":"24","author":"J Sonnenberg","year":"1989","unstructured":"Sonnenberg J, Mitchelmore C, Macgregor-Leon P, Hempstead J, Morgan J, Curran T (1989) Glutamate receptor agonists increase the expression of Fos, Fra, and AP-1 DNA binding activity in the mammalian brain. J Neurosci Res 24:72\u201380","journal-title":"J Neurosci Res"},{"key":"1644_CR130","first-page":"1","volume":"17","author":"Y Li","year":"2016","unstructured":"Li Y, Zhang Q, Qi D, Zhang L, Yi L, Li Q et al (2016) Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-\u043aB. J Headache Pain 17:1\u20139","journal-title":"J Headache Pain"},{"key":"1644_CR131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706","journal-title":"N Engl J Med"},{"key":"1644_CR132","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1177\/0333102419861726","volume":"39","author":"SL Christensen","year":"2019","unstructured":"Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G (2019) Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Cephalalgia 39:1827\u20131837","journal-title":"Cephalalgia"},{"key":"1644_CR133","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neuroscience.2016.04.046","volume":"328","author":"S Miller","year":"2016","unstructured":"Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C et al (2016) Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience 328:165\u2013183","journal-title":"Neuroscience"},{"key":"1644_CR134","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","volume":"34","author":"R Burstein","year":"2014","unstructured":"Burstein R, Zhang X, Levy D, Aoki KR, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34:853\u2013869","journal-title":"Cephalalgia"},{"key":"1644_CR135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/toxins14080529","volume":"14","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tonin P, Nicotera P, Vulnera M, Altieri GC, Tarsitano A et al (2022) Pooled analysis of real-world evidence supports anti-CGRP mAbs and OnabotulinumtoxinA combined trial in chronic migraine. Toxins 14:529","journal-title":"Toxins"},{"key":"1644_CR136","doi-asserted-by":"crossref","first-page":"033310242211478","DOI":"10.1177\/03331024221147881","volume":"43","author":"S Ashina","year":"2023","unstructured":"Ashina S, Melo-Carrillo A, Szabo E, Borsook D, Burstein R (2023) Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: a prospective quantitative sensory testing study (NCT04271202). Cephalalgia 43:03331024221147881","journal-title":"Cephalalgia"},{"key":"1644_CR137","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394:1765\u20131774","journal-title":"Lancet"},{"key":"1644_CR138","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61:363\u2013372","journal-title":"Headache"},{"key":"1644_CR139","doi-asserted-by":"crossref","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268:3789\u20133798","DOI":"10.1007\/s00415-021-10523-8"},{"key":"1644_CR140","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/head.14390","volume":"62","author":"D Kudrow","year":"2022","unstructured":"Kudrow D, Nguyen L, Semler J, Stroud C, Samaan K, Hoban DB et al (2022) A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist. Headache 62:1164\u20131176","journal-title":"Headache"},{"key":"1644_CR141","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/head.14336","volume":"62","author":"KW Johnson","year":"2022","unstructured":"Johnson KW, Li X, Huang X, Heinz BA, Yu J, Li B (2022) Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists. Headache 62:848\u2013857","journal-title":"Headache"},{"key":"1644_CR142","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291\u2013301","journal-title":"Cephalalgia"},{"key":"1644_CR143","doi-asserted-by":"crossref","unstructured":"Hanna M, Ivans A, Stringfellow J, Jensen C, Coric V, Croop R (2020) Oral rimegepant produces no significant effect on blood pressure when administered concomitantly with SC sumatriptan (4007). Neurology 94 (15 Supplement):4007","DOI":"10.1212\/WNL.94.15_supplement.4007"},{"key":"1644_CR144","doi-asserted-by":"crossref","first-page":"251581632110079","DOI":"10.1177\/25158163211007922","volume":"4","author":"R Croop","year":"2021","unstructured":"Croop R, Ivans A, Anderson MS, Stringfellow J, Bertz R, Hanna M et al (2021) A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Rep 4:25158163211007920","journal-title":"Cephalalgia Rep"},{"key":"1644_CR145","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC et al (2020) Safety of Rimegepant, an oral cgrp receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache 60:1734\u20131742","journal-title":"Headache"},{"key":"1644_CR146","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","volume":"89","author":"H Ghanizada","year":"2021","unstructured":"Ghanizada H, Al-Karagholi MA, Walker CS, Arngrim N, Rees T, Petersen J et al (2021) Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 89:1157\u20131171","journal-title":"Ann Neurol"},{"key":"1644_CR147","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0333102420977106","volume":"41","author":"P Irimia","year":"2020","unstructured":"Irimia P, Martinez-Valbuena I, Minguez-Olaondo A, Dominguez-Vivero C, Sanchez-Arias JA, Martinez-Vila E et al (2020) Interictal amylin levels in chronic migraine patients: a case-control study. Cephalalgia 41:604\u2013612","journal-title":"Cephalalgia"},{"key":"1644_CR148","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798\u20131808","journal-title":"Cephalalgia"},{"key":"1644_CR149","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/HJH.0000000000001649","volume":"36","author":"L Zhai","year":"2018","unstructured":"Zhai L, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Tanaka M et al (2018) Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline. J Hypertens 36:876\u2013891","journal-title":"J Hypertens"},{"key":"1644_CR150","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1177\/0333102419863027","volume":"39","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Dirven C et al (2019) Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia 39:1735\u20131744","journal-title":"Cephalalgia"},{"key":"1644_CR151","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13316","volume":"58","author":"C Depre","year":"2018","unstructured":"Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA et al (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 58:715\u2013723","journal-title":"Headache"},{"key":"1644_CR152","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ahj.2007.10.019","volume":"155","author":"KH Humphries","year":"2008","unstructured":"Humphries KH, Pu A, Gao M, Carere RG, Pilote L (2008) Angina with \u201cnormal\u201d coronary arteries: sex differences in outcomes. Am Heart J 155:375\u2013381","journal-title":"Am Heart J"},{"key":"1644_CR153","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","volume":"23","author":"AO G\u00e9rard","year":"2022","unstructured":"G\u00e9rard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lant\u00e9ri-Minet M et al (2022) Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain 23:53","journal-title":"J Headache Pain"},{"key":"1644_CR154","doi-asserted-by":"crossref","first-page":"033310242211435","DOI":"10.1177\/03331024221143538","volume":"43","author":"M Ruiz","year":"2023","unstructured":"Ruiz M, Cocores A, Tosti A, Goadsby PJ, Monteith TS (2023) Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases Series, evaluation of FAERS, and literature review. Cephalalgia 43:03331024221143538","journal-title":"Cephalalgia"},{"key":"1644_CR155","doi-asserted-by":"crossref","unstructured":"Wee NK, Novak S, Ghosh D, Root SH, Dickerson IM, Kalajzic I (2023) Inhibition of CGRP signaling impairs fracture healing in mice. J Orthop Res 41:1228\u20131239","DOI":"10.1002\/jor.25474"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01644-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T08:46:50Z","timestamp":1703148410000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01644-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":155,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01644-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ALR, CG, ES, AD, DB, HN, LM, NC, and TG do not report a conflict of interest. EC has received honoraria from Novartis, Chiesi, Lundbeck, Medscape. PPR has received honoraria as a consultant and speaker, in the last three years, for: AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; and, has received funding for clinical trials from Alder, AbbVie, Amgen, Biohaven, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva. She is the Honorary Secretary of the International Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology. She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of\n                      \n                      . Pozo-Rosich P does not own stocks from any pharmaceutical company. RB is the John Hedley-Whyte Professor of Anesthesia and Neuroscience at the Beth Israel Deaconess Medical Center and Harvard Medical School. He has received research support from the NIH: R01 NS094198-01A1, R37 NS079678, R01NS095655, R01 NS104296, R21 NS106345, Allergan, Teva, Dr. Reddy, Eli Lilly, Trigemina and the Migraine Research Foundation. He is a reviewer for NINDS, holds stock options in AllayLampand Percept; serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, CGRP Diagnostic, Dr. Reddy\u2019s Laboratory, ElectroCore, Eli Lilly, GlaxoSmithKline, Merck, Pernix, Theranica, Teva, and Trigemina. CME fees from Healthlogix, Medlogix, WebMD\/Medscape, and Patents 9061025, 11732265.1, 10806890, US2021-0015908, WO21007165, US2021-0128724, WO21005497. JH received honoraria for consulting activities and\/or serving on advisory boards and\/or as a speaker from Allergan, Abbvie, Autonomic Technologies Inc., Cannovex BV, Chordate Medical AB, Eli Lilly, Hormosan Pharma, Lundbeck, MD-Horizonte, Novartis, Sanofi and Teva. He received personal fees for Medico-Legal work as well as from NEJM Journal Watch, Oxford University Press, Quintessence Publishing, Sage Publishing and Springer Healthcare. He holds stock options from Chordate Medical AB. He also reports a research grant from Bristol Myers Squibb. Jan Hoffmann serves as Associate Editor for Cephalalgia, Cephalalgia Reports, Journal of Headache and Facial Pain, Journal of Oral & Facial Pain and Headache as well as for Frontiers in Pain Research. He is an elected member of the Board of Trustees as well as the Science and Research Committee of the International Headache Society (IHS) and serves as a Council Member and Treasurer of the British Association for the Study of Headache (BASH). The article-processing charges for the article has been kindly sponsored by the European Headache Federation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}